Investigator Initiated Study: Digital Therapeutics
Investigator-Initiated Studies (IIS)
In general, IIS are not registrational studies, and they may be proof of concept or exploratory in nature. The budget for these studies should reflect fair market value for all costs and cannot include direct salary support for the principal investigator.
Boehringer Ingelheim may provide financial support and/or drugs for an approved IIS. BI does not serve as the regulatory sponsor for IIS. Investigators are required to apply for support via an online application process.
Although the research interests listed within the following therapeutic areas are of focus to BI, other research interests may be considered.
Digital Therapeutics
-
Increase the clinician’s awareness of the current unmet medical needs and burden of disease in patients with schizophrenia, including cognitive and negative symptoms associated with schizophrenia as well as the potential utility of digital therapeutics in psychiatry, including schizophrenia
-
Improve the clinician’s understanding of the management and limitations of treating cognitive and negative symptoms of schizophrenia, as well as ongoing developments in clinical research in schizophrenia and digital therapeutics in psychiatry
Proposals in the following areas are not being considered
Biosimilars and Fibrosing ILDs
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.